Navigation Links
Advanced Life Sciences Announces Delisting From Nasdaq and Pending Quotation of its Common Stock on the OTC Bulletin Board

- Company Appeals Delisting Decision to Nasdaq Listing and Hearing Review Council -

CHICAGO, May 4 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS) announced today that the Nasdaq Listing Qualifications Panel (the "Panel") has determined to suspend trading in the Company's common stock from the Nasdaq Stock Market effective at the open of business on Tuesday, May 5, 2009. The Panel's decision was based on the Company's inability to evidence compliance with the $2.5 million shareholders' equity requirement or the $35 million market value of listed securities requirement. The Company requested that the Nasdaq Listing and Hearing Review Council (the "Listing Council") issue a stay on the Panel's decision to suspend the Company's common stock from trading but the Listing Council informed the Company today that it would not call the matter for review. The Company has formally appealed the decision to the Listing Council, which may affirm, modify, reverse, dismiss, or remand the decision.

The Company also announced that it has engaged a market maker that has filed a Form 211 application to quote the Company's common stock on the OTC Bulletin Board (OTCBB). The application is pending with Financial Industry Regulatory Authority (FINRA). Listing on the OTCBB will allow the Company to sell shares of common stock under its Standby Equity Distribution Agreement (SEDA) with YA Global Investments, L.P., an affiliate of Yorkville Advisors, which provides for the sale of up to $15.0 million of shares of the Company's common stock over a two-year commitment period. The Company's common stock will also be eligible for trading on the Pink Sheets beginning on Tuesday, May 5, 2009.

"While we are disappointed by Nasdaq's determination, we will continue to appeal the decision as the OTCBB begins quotation of our securities," stated Dr. Michael T. Flavin, chairman and chief executive officer of Advanced Life Sciences. "The Company has been current in its filings with the SEC and is preparing for a major corporate milestone in our upcoming FDA Advisory Committee meeting scheduled for June 2, 2009 to review the NDA for cethromycin as a treatment for community-acquired pneumonia. As we prepare for that event, we look forward to reestablishing the active market for our shares on the OTC Bulletin Board."

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. For more information, please visit us on the web at

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
3. Advanced Age No Bar to Liver Transplant
4. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
5. Advanced technologies aim to transform the coaching of top athletes
6. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
7. Advanced Life Sciences Joins NASDAQ Capital Market
8. Experimental drug shows promise in advanced kidney cancer
9. TCS Healthcare Technologies Announces Full Integration of Case Management Adherence Guidelines into Acuity Advanced Care(TM) System
10. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
(Date:11/26/2015)... ... 2015 , ... Somu Sivaramakrishnan announced today that he joined ... offers travelers, value and care based Travel Services, including exclusive pricing on a ... cabin upgrades and special amenities such as, shore excursions, discounted fares, travel gifts ...
(Date:11/26/2015)... BOSTON, Mass. (PRWEB) , ... November 26, 2015 ... ... a thorough second medical opinion process, participated in the 61st annual Employee Benefits ... Benefit Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... aggressive than those found on mammography, according to a study published online in ... cancers not seen on mammography may necessitate a change in treatment. , Breast ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... been recognized once again for its stellar workplace culture with the company’s Cincinnati ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  The American ... and Gynecologists (ACOG), and the March of Dimes ... Protecting Our Infants Act of 2015 ... number of newborns born exposed to drugs, such ... the bill,s introduction, all three organizations have worked ...
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... announced that Chief Executive Officer Antonius Schuh, Ph.D., is ... th Annual Piper Jaffray Healthcare Conference. ... New York Palace Hotel in New York ... p.m. EST. Mr. Schuh will be available for one-on-one ...
Breaking Medicine Technology: